Larimar Therapeutics, Inc.
NASDAQ:LRMR
7.57 (USD) • At close November 4, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Larimar Therapeutics, Inc. |
Symbool | LRMR |
Munteenheid | USD |
Prijs | 7.57 |
Beurswaarde | 483,015,962 |
Dividendpercentage | 0% |
52-weken bereik | 2.18 - 13.68 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Carole S. Ben-Maimon M.D. |
Website | https://www.larimartx.com |
An error occurred while fetching data.
Over Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)